Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A | P04350 | 2/20 | 0.36 |
| ▸ | TUBB | P07437 | 2/20 | 0.36 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.36 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.36 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.36 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.36 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.36 |
| ▸ | TUBB2A | Q13885 | 2/20 | 0.36 |
| ▸ | TUBB8 | Q3ZCM7 | 2/20 | 0.36 |
| ▸ | TUBA3E | Q6PEY2 | 2/20 | 0.36 |
| ▸ | TUBA1A | Q71U36 | 2/20 | 0.36 |
| ▸ | TUBA1C | Q9BQE3 | 2/20 | 0.36 |
| ▸ | TUBB6 | Q9BUF5 | 2/20 | 0.36 |
| ▸ | TUBB2B | Q9BVA1 | 2/20 | 0.36 |
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.36 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 4/20 | 0.33 |
| ▸ | THRA | P10827 | 3/20 | 0.33 |
| ▸ | GCGR | P47871 | 2/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL282106 | 0.85 | THRB (0.48) | THRBTHRA | |
| SCHEMBL31041193 | 0.85 | THRB (0.48) | THRBTHRA | |
| SCHEMBL3156467 | 0.83 | THRB (0.53) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL31041196 | 0.82 | THRB (0.37) | THRBTHRARORCLMNAALOX15 | |
| SCHEMBL27666398 | 0.81 | THRA (0.48) | THRBTHRA | |
| SCHEMBL285893 | 0.80 | THRB (0.37) | THRBTHRA | |
| SCHEMBL25950026 | 0.80 | THRB (0.43) | THRBTHRARORC | |
| SCHEMBL282283 | 0.78 | THRB (0.39) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL28978485 | 0.78 | THRB (0.44) | THRBTHRARORCALOX15ALOX12 | |
| SCHEMBL6263796 | 0.77 | THRB (0.42) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1689383-B1 | NOVEL PHOSPHORUS-CONTAINING THYROMIMETICS | METABASIS THERAPEUTICS INC (US) | 2012-10-31 | — | — | EP | disclosed |
| EP-2428516-A1 | Novel phosphorus-containing thyromimetics | Metabasis Therapeutics, Inc. (US) | 2012-03-14 | — | — | EP | disclosed |
| US-7829552-B2 | Phosphorus-containing thyromimetics | METABASIS THERAPEUTICS, INC. (US) | 2010-11-09 | — | — | US | disclosed |
| US-20100081634-A1 | Novel Phosphorus-Containing Thyromimetics | METABASIS THERAPEUTICS, INC. (US) | 2010-04-01 | — | — | US | disclosed |
| US-20090118236-A1 | Novel Phosphorus-Containing Thyromimetics | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2009-05-07 | — | — | US | disclosed |
| US-7514419-B2 | Phosphorus-containing thyromimetics | METABASIS THERAPEUTICS, INC. (US) | 2009-04-07 | — | — | US | disclosed |
| US-20090028925-A1 | Novel Phosphinic Acid-Containing Thyromimetics | METABASIS THERAPEUTICS, INC. | 2009-01-29 | — | — | US | disclosed |
| CN-101189248-A | Novel phosphorus-containing thyromimetics | METABASIS THERAPEUTICS INC (US) | 2008-05-28 | — | — | CN | disclosed |
| CN-101180097-A | Novel phosphinic acid-containing thyromimetics | METABASIS THERAPEUTICS INC (US) | 2008-05-14 | — | — | CN | disclosed |
| CN-1882327-A | Novel phosphorus-containing thyromimetics | METABASIS THERAPEUTICS INC (US) | 2006-12-20 | — | — | CN | disclosed |
| US-20060046980-A1 | Novel phosphorus-containing thyromimetics | METABASIS THERAPEUTICS, INC. | 2006-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081634-A1 | Novel Phosphorus-Containing Thyromimetics | PYGL, THRA, THOP1 | TUBB4A 4348/4885TUBB 4441/4885TUBA3C 4034/4885 |
| US-20060046980-A1 | Novel phosphorus-containing thyromimetics | PYGL, THRA, THOP1 | TUBB4A 4348/4885TUBB 4441/4885TUBA3C 4034/4885 |
| US-20090118236-A1 | Novel Phosphorus-Containing Thyromimetics | THRA, PYGL, THRB | TUBB4A 4096/4885TUBB 4304/4885TUBA3C 3899/4885 |
| US-20090028925-A1 | Novel Phosphinic Acid-Containing Thyromimetics | PYGL, PHOSPHO1, LIPE | TUBB4A 4345/4885TUBB 4414/4885TUBA3C 4153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.